Contribute Try STAT+ Today

Despite large amounts of taxpayer funding, dozens of the largest U.S. universities failed to commit to policies ensuring that essential medicines and health technologies generated by their labs would be equally accessible around the globe, a new analysis finds.

Of the 60 universities that were examined, only 22% committed to specific global access licensing strategies and just 12% adopted licensing that places a priority on generic production of medicines for lower-income countries, according to the Universities Allied Essential Medicines, an organization led by medical students who seek to improve affordable access worldwide.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED

What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.